Drug · CHEMBL779
TADALAFIL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. TADALAFIL. Drugs and targets, record CHEMBL779. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL779
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Adcirca, Adcirca (previously tadalafil lilly), Chewtadzy, Cialis, Tadalafil component of entadfi, Tadalafil component of opsynvi, Tadalafil lilly, Tadalafil mylan, Tadliq, Talmanco (previously tadalafil generics)
- ChEMBL
- Other names
- Chewtadzy, IC-351, IC351, LY-450190, LY450190, NSC-750236, NSC-759172, Tadalafil mylan, Tadalafilo, Trans-tadalafil
- ChEMBL
- Open Targets' highest stage
- Approval, for 5 of its 55 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | Phosphodiesterase 5A inhibitor | INHIBITOR | https://conductscience.org/library/genes/8654 |
Source ChEMBL
Diseases55
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| erectile dysfunction | Approval | ATC, DailyMed, EMA Human Drugs, PMDA and TTD | 82 | 64 | https://conductscience.org/library/drugs?q=MONDO_0005362 |
| benign prostatic hyperplasia | Approval | DailyMed and PMDA | 30 | 20 | https://conductscience.org/library/drugs?q=MONDO_0010811 |
| pulmonary arterial hypertension | Approval | DailyMed, EMA Human Drugs and PMDA | 22 | 18 | https://conductscience.org/library/drugs?q=MONDO_0015924 |
| pulmonary hypertension | Approval | EMA Human Drugs | 12 | 10 | https://conductscience.org/library/drugs?q=MONDO_0005149 |
| lower urinary tract symptom | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=EFO_0008008 |
| Duchenne muscular dystrophy | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0010679 |
| chronic obstructive pulmonary disease | Phase 2 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005002 |
| head and neck squamous cell carcinoma | Phase 2 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0010150 |
| hypertensive disorder | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005044 |
| Insulin resistance | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=HP_0000855 |
1 to 10 of 55Source Open Targets
See all 55 diseasesTrials238
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00384930 | Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia | Phase 2/3 | 1,058 | 2009-08-19 | tadalafil | Its name | ClinicalTrials.gov |
| NCT01937871 | A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED) | Phase 3 | 909 | 2017-02-07 | tadalafil | Its name | ClinicalTrials.gov |
| NCT01122264 | A Study in Patients With Erectile Dysfunction | Phase 4 | 770 | 2012-10-19 | tadalafil | Its name | ClinicalTrials.gov |
| NCT01139762 | A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms | Phase 3 | 696 | 2013-02-27 | tadalafil | Its name | ClinicalTrials.gov |
| NCT02224846 | A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction | Phase 4 | 635 | 2017-10-27 | tadalafil | Its name | ClinicalTrials.gov |
| NCT01130532 | A Study in Erectile Dysfunction | Phase 4 | 623 | 2013-01-04 | tadalafil | Its name | ClinicalTrials.gov |
| NCT00861757 | Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia | Phase 3 | 612 | 2011-06-13 | tadalafil | Its name | ClinicalTrials.gov |
| NCT01178073 | A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) | Phase 3 | 610 | 2015-04-28 | tadalafil | Its name | ClinicalTrials.gov |
| NCT01460342 | Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH) | Phase 3 | 610 | 2013-09-25 | tadalafil | Its name | ClinicalTrials.gov |
| NCT00855582 | A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia | Phase 3 | 606 | 2011-06-30 | tadalafil | Its name | ClinicalTrials.gov |
1 to 10 of 238
See all 238 trialsComparisons in its trials41
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 2.5 mg/5 mg Tadalafil vs 5 mg Tadalafil: serious adverse events | 15 of 210 | 17 of 421 | 631 | NCT02224846 | Trial comparisons |
| Tadalafil vs Placebo: serious adverse events | 2 of 306 | 1 of 304 | 610 | NCT01460342 | Trial comparisons |
| Tadalafil vs Placebo: serious adverse events | 0 of 167 | 0 of 161 | 328 | NCT02431754 | Trial comparisons |
| Tadalafil vs Placebo: serious adverse events | 2 of 161 | 0 of 164 | 325 | NCT00827242 | Trial comparisons |
| Tadalafil vs Placebo: serious adverse events | 2 of 158 | 3 of 160 | 318 | NCT00848081 | Trial comparisons |
| Tadalafil vs Placebo: Number of Men With Treatment-emergent Dizziness | 11 of 158 | 9 of 159 | 317 | NCT00848081 | Trial comparisons |
| Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo): deaths from any cause | 4 of 119 | 12 of 127 | 246 | NCT02558231 | Trial comparisons |
| Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo): serious adverse events | 58 of 119 | 48 of 127 | 246 | NCT02558231 | Trial comparisons |
| Riociguat vs PDE-5i: deaths from any cause | 0 of 111 | 4 of 114 | 225 | NCT02891850 | Trial comparisons |
| Riociguat vs PDE-5i: serious adverse events | 8 of 111 | 19 of 114 | 225 | NCT02891850 | Trial comparisons |
1 to 10 of 41
See all 41 comparisons in its trialsPapers from its trials111
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials8
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Digit Span Test | 1 | 0 | ConductCognition |
| One-Touch Tower Planning | 1 | 0 | ConductCognition |
| Paired Associate Learning | 1 | 0 | ConductCognition |
| Rapid Visual Information Processing | 1 | 0 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
| Tower Planning | 1 | 0 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
| Trail Making Test B | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL779
GET https://conductscience.org/api/drugs/v1/CHEMBL779/diseases?page=2